Consolidated Statements of Operations - USD ($)	3 Months Ended	9 Months Ended
Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Operating Expenses:
Research and development	$ 3,187,024	$ 2,958,593	$ 11,190,939	$ 13,496,045
General and administrative	2,942,877	2,768,927	9,081,806	10,513,570
Total operating expenses	6,129,901	5,727,520	20,272,745	24,009,615
Operating loss	(6,129,901)	(5,727,520)	(20,272,745)	(24,009,615)
Other income (expense):
Other income (expense), net	176,855	5,117	137,288	19,559
Interest expense	(8,687)	(368,364)	(372,099)	(1,601,421)
Other income (expense)	168,168	(363,247)	(234,811)	(1,581,862)
Loss from continuing operations before benefit from income taxes and noncontrolling interests	(5,961,733)	(6,090,767)	(20,507,556)	(25,591,477)
Benefit from income taxes	(2,413,951)	0	(8,301,494)	0
Net loss from continuing operations	(3,547,782)	(6,090,767)	(12,206,062)	(25,591,477)
Discontinued operations - net of taxes	0	(1,196,838)	37,329,963	(1,628,694)
Net (loss) income	(3,547,782)	(7,287,605)	25,123,901	(27,220,171)
Less - net loss from continuing operations attributable to noncontrolling interests	(119,342)	(59,423)	(149,509)	(187,126)
Less - net loss from discontinued operations attributable to noncontrolling interests	0	(345,649)	(568,156)	(334,879)
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	(3,428,440)	(6,882,533)	25,841,566	(26,698,166)
Amounts Attributable to Caladrius Inc. common stockholders:
Loss from continuing operations	(3,428,440)	(6,031,344)	(12,056,553)	(25,404,351)
Income (loss) from discontinued operations - net of taxes	0	(851,189)	37,898,119	(1,293,815)
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ (3,428,440)	$ (6,882,533)	$ 25,841,566	$ (26,698,166)
Basic and diluted income (loss) per share
Continuing operations (in usd per share)	$ (0.38)	$ (0.95)	$ (1.37)	$ (4.23)
Discontinued operations (in usd per share)	0.00	(0.13)	4.30	(0.22)
Caladrius Biosciences, Inc. common stockholders (in usd per share)	$ (0.38)	$ (1.09)	$ 2.94	$ (4.45)
Weighted average common shares outstanding:
Basic and diluted shares	9,093,880	6,323,427	8,803,784	6,001,572

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

No definition available.